REGN: Fair Outlook As LAG 3 Setback Reshapes Pipeline And Product Prospects

Analysts have trimmed their fair value estimate for Regeneron Pharmaceuticals to $641 from $730, reflecting lower assumed profit margins and a reduced future P/E multiple after the recent fianlimab LAG-3 trial setbacks and related cuts to price targets across the Street.

Analyst Commentary

Street research has turned more cautious on Regeneron following the failed Phase 3 LAG-3 melanoma trial for fianlimab, with a series of reduced price targets and several rating downgrades. While some institutions continue to highlight strengths in Dupixent and other core drugs, the immediate focus has shifted to pipeline execution risk, trial uncertainty, and the potential impact on earnings expectations.

Most recent notes point to the Phase 3 miss in first line metastatic melanoma progression free survival as the key trigger for model changes. Several bearish analysts have removed or sharply reduced fianlimab revenue assumptions, pushed out potential launch timelines, and cut valuation multiples applied to Regeneron, particularly on earnings in the second half of this decade.

Despite these cuts, some large firms, including JPMorgan, continue to point to the company’s existing assets and cash position as an important support for the stock. However, the balance of commentary in the latest batch of reports is clearly more guarded, with sentiment affected by what some describe as repeated pipeline disappointments and questions around the strategy behind late stage studies.

Bearish Takeaways

Multiple bearish analysts have cut price targets, in some cases by more than US$100 per share, following the LAG-3 fianlimab miss in Phase 3 melanoma. They cite reduced modeled revenue, lower assumed margins, and discounted P/E multiples.
Two firms, including Citi and Leerink, downgraded Regeneron to Neutral or Market Perform and flagged high profile pipeline disappointments and LAG-3 failure as key reasons for more cautious ratings and trimmed earnings expectations.
Concerns around Eylea and potential erosion from biosimilar competition are cited as additional execution and cash flow risks, with Leerink explicitly pointing to possible revenue and EPS downside relative to prior expectations.
Some bearish analysts question the pipeline’s differentiation, describing recent setbacks as me too and warning that investor trust in the company’s R&D strategy could remain under pressure. This in turn weighs on how much investors may be willing to pay for future growth.

What's in the News

Regeneron reached a deal to lower prices on Otarmeni, its newly approved gene therapy for ultra rare OTOF related hearing loss, after the U.S. FDA granted accelerated approval and the company committed to provide the therapy at no cost to clinically eligible patients in the U.S. (Bloomberg, FDA approval release)
The FDA granted accelerated approval for Otarmeni for pediatric and adult patients with severe to profound sensorineural hearing loss linked to biallelic OTOF variants, with continued approval tied to confirmatory data from the ongoing CHORD trial. (FDA approval release)
Regeneron announced highly positive Phase 1/2 LINKER AL2 data for Lynozyfic in second line plus systemic AL amyloidosis, with all patients responding hematologically and the highest dose cohort reaching a 100% complete response rate, while the registrational Phase 2 portion continues. (Company trial update)
The company disclosed that its Phase 3 melanoma trial of fianlimab plus cemiplimab did not hit statistical significance on progression free survival versus pembrolizumab, with detailed data to follow and a separate head to head Phase 3 against Opdualag still in progress. (Company trial update)
Regeneron and Sanofi reported Phase 4 REMODEL data showing Dupixent improved esophageal function and structural disease measures in adults with eosinophilic esophagitis at week 24, building on its role as an approved biologic for this condition. (Company trial update)

Valuation Changes

Fair value estimate reduced from $730.00 to $641.00, reflecting a cut of roughly $89 per share.
Discount rate adjusted slightly lower from 7.21% to 7.18%, indicating only a modest change in the risk assumption.
Revenue growth now modeled at 6.13% versus 5.87% previously, a small upward revision to the top line growth assumption in dollar terms.
Net profit margin reduced from 29.91% to 27.03%, indicating a more conservative view on future profitability in dollar earnings.
Future P/E trimmed from 16.6x to 15.7x, pointing to a slightly lower multiple applied to expected earnings.

9 views

Key Takeaways

Reliance on a few key products and increasing biosimilar competition threaten revenue growth and earnings stability as healthcare reforms pressure pricing power.
Rising R&D expenses and demographic headwinds may limit the long-term growth potential and sustainability of current revenue streams.
Strong commercial execution, a diversified late-stage pipeline, strategic portfolio transitions, sustained R&D investment, and favorable industry trends position Regeneron for continued long-term growth.

Catalysts

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.What are the underlying business or industry changes driving this perspective?

Long-term global pricing pressures and political efforts to reform healthcare costs, especially in the United States, threaten to significantly erode Regeneron's pricing power across key franchises such as Dupixent and EYLEA, thus limiting future revenue growth and compressing net margins over the next several years.
Regeneron's heavy reliance on EYLEA and now EYLEA HD for a substantial portion of overall revenues leaves it acutely vulnerable to mounting biosimilar competition and alternative therapies following patent expirations; this is already becoming reality with reported sales declines and is expected to accelerate, risking a rapid erosion of top-line growth and earnings stability.
Demographic headwinds in developed markets-specifically the interplay between aging patient populations and sharply declining birthrates-pose a material long-term risk by eventually shrinking the addressable patient pool for Regeneron's core age-related disease products, constraining growth potential and reducing the sustainability of current revenue trajectories.
Intensifying global competition, not only from established biopharma players but also from smaller, more agile companies employing innovative modalities such as mRNA and gene editing, threatens Regeneron's market share and exclusivity for new and existing biologics, particularly as regulatory agencies expedite rival approvals, further pressuring future sales growth.
Escalating research and development costs tied to increasingly complex biologics and the need to advance a broad and expensive late-stage pipeline may outpace any revenue gains; if new launches or lifecycle enhancements fail to deliver expected returns, this dynamic will compress operating margins and ultimately undermine long-term earnings growth.

Regeneron Pharmaceuticals Earnings and Revenue Growth

Regeneron Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more pessimistic perspective on Regeneron Pharmaceuticals compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
The bearish analysts are assuming Regeneron Pharmaceuticals's revenue will grow by 6.1% annually over the next 3 years.
The bearish analysts assume that profit margins will shrink from 29.6% today to 27.0% in 3 years time.
The bearish analysts expect earnings to reach $4.8 billion (and earnings per share of $47.16) by about May 2029, up from $4.4 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $7.6 billion.
In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 15.8x on those 2029 earnings, up from 14.7x today. This future PE is lower than the current PE for the US Biotechs industry at 16.2x.
The bearish analysts expect the number of shares outstanding to decline by 1.69% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.18%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Regeneron has demonstrated robust commercial execution with significant year-over-year growth in core products like Dupixent (21% global net sales growth, now annualizing at over $17 billion) and Libtayo (25% global net sales growth), supporting continued revenue and profit expansion over the long term.
The company is transitioning its ophthalmology portfolio from the declining EYLEA franchise to EYLEA HD, which showed strong demand growth (16% sequential increase, $393 million in quarterly US net sales), suggesting Regeneron can mitigate biosimilar erosion and recapture market share, which would help stabilize or enhance overall revenue.
Regeneron's pipeline is highly diversified, with approximately 45 product candidates spanning oncology, obesity, hematology, genetics, and more; late-stage advancements like Lynozyfic, odronextamab, and the obesity/bariatric pipeline offer multiple potential blockbuster launches, which could materially boost future revenue and earnings.
Sustainable R&D investment supported by a robust balance sheet ($17.5 billion in cash/marketable securities, only $2.7 billion in debt) provides the company flexibility to continue pipeline development, strategic acquisitions, and shareholder returns (buybacks and dividends), thus supporting net margin improvement and financial resilience.
Favorable long-term secular trends-including increasing prevalence of chronic and age-related diseases, rising global demand for biologics, and expanding insurance coverage-are tailwinds for Regeneron's product portfolio, which is well-positioned in high-growth therapeutic areas, bolstering the outlook for both top-line and bottom-line growth over the coming years.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bearish price target for Regeneron Pharmaceuticals is $641.0, which represents up to two standard deviations below the consensus price target of $833.31. This valuation is based on what can be assumed as the expectations of Regeneron Pharmaceuticals's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $1000.0, and the most bearish reporting a price target of just $641.0.
In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $17.8 billion, earnings will come to $4.8 billion, and it would be trading on a PE ratio of 15.8x, assuming you use a discount rate of 7.2%.
Given the current share price of $638.88, the analyst price target of $641.0 is 0.3% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Regeneron Pharmaceuticals?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

US Healthcare Reforms And Biosimilars Will Erode Margins